Envista to acquire Osteogenics

By DrBicuspid.com staff writers

May 19, 2022 -- Dental products company Envista Holdings has signed a deal to acquire bone grafting product developer Osteogenics Biomedical, which includes Allotech and OBI Biologics.

Details of the transaction, which is expected to close in the third quarter of 2022, were not disclosed. Also, the deal is not subject to a financing condition or shareholder vote.

Primarily sold under the brand name Cytoplast, Osteogenics offers bone grafting products for periodontal and oral and maxillofacial surgical procedures.

Copyright © 2022 DrBicuspid.com

To read this and get access to all of the exclusive content on DrBicuspid.com create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a DrBicuspid.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking